Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Martinez homers with two outs in the 9th inning to end Braves' combined noMinnesota unfurls new state flag atop the capitol for the first time SaturdayLithuania elections: Lithuanians vote as anxieties rise over Russia and Ukraine warMan charged with overturning portTürkiye raises yearLuis Muriel scores first 2 MLS goals, Gallese stops late PK as Orlando City beats Union 3Sherpa guide Kami Rita scales Mount Everest for 29th time, extending his own record againMatt Chapman's grand slam leads the Giants past the Reds 5Putin says four gunmen in Moscow terrorist attack arrestedSherpa guide Kami Rita scales Mount Everest for 29th time, extending his own record again
2.2628s , 6497.2734375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Culture Circuit news portal